Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
Amylyx Pharmaceuticals announced the peer-reviewed publication of Week 24 and Week 48 data from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, published in The Journal of Clinical Investigation. The results showed continued improvement in pancreatic beta cell function and glycemic control, alongside stabilization of visual acuity over 48 weeks in the 12-participant open-label study.
Key figures
- Drug Name
- AMX0035
- Phase Of Trial
- Phase 2
- Trial name
- HELIOS
- Follow up weeks
- 4
- Participant count
- 12
- Trial duration weeks
- 208
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.